[{"orgOrder":0,"company":"Negev Labs","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Negev Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Negev Labs \/ Negev Labs","highestDevelopmentStatusID":"4","companyTruncated":"Negev Labs \/ Negev Labs"},{"orgOrder":0,"company":"Negev Labs","sponsor":"Negev Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Negev Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Negev Labs \/ Negev Labs","highestDevelopmentStatusID":"2","companyTruncated":"Negev Labs \/ Negev Labs"},{"orgOrder":0,"company":"Negev Labs","sponsor":"Hadassah Brain Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Negev Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Negev Labs \/ Hadassah Brain Labs","highestDevelopmentStatusID":"2","companyTruncated":"Negev Labs \/ Hadassah Brain Labs"}]

Find Clinical Drug Pipeline Developments & Deals by Negev Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The acquisition of Beckley Psytech's Ophthalmology development program aligns with Negev's mission to develop the full therapeutic potential of neuroplastogens.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : Beckley Psytech

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The ASRI licensing agreement provides Negev Labs access to a vast library of drug candidates for the treatment of psychiatric disorder .

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Discovery

                          Recipient : Alexander Shulgin Research Institute

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Negev Labs and Hadassah Brain Labs collaborate to advance non-hallucinogenic neuroplastogens, redefining safe and accessible psychedelic-inspired therapies for psychiatric and neurological disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Discovery

                          Sponsor : Hadassah Brain Labs

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank